A large, retrospective study conducted by scientists at The University of Texas at San Antonio suggests that people taking glucagon-like peptide-1 (GLP-1) receptor agonists — medications that are widely prescribed for metabolic disease — have a significantly lower risk of developing colorectal cancer compared with those taking aspirin.

  This story was first published in the February 2026 issue of the Bexar County Medical Society’s San Antonio Medicine magazine. New face of head and neck cancer A healthy 40-year-old man visits his primary care physician for a mass on his neck. He doesn’t smoke, has no risk factors for head and neck cancer, […]

UT Health San Antonio Multispecialty and Research Hospital became the first in South Texas to use an emerging and less-invasive treatment called radiofrequency ablation on a comorbid patient with a pancreatic cancer tumor that couldn’t be removed by surgery.

UT Health San Antonio received nearly $3 million in new academic and prevention awards as part of the latest, almost $154 million funding round announced on Nov. 19 by the Cancer Prevention Research Institute of Texas (CPRIT).

Research scientists and clinicians at UT Health San Antonio are working to halt one of the most persistent bacterial infections that silently affects millions of people worldwide.

UT Health San Antonio’s advanced endoscopy team leads efforts in early detection and prevention Gastrointestinal cancers were previously believed to primarily affect older adults, but over the past two decades, rates of these cancers have increased dramatically in people under age 50. A new report from the Dana-Farber Cancer Institute reveals that colorectal, pancreatic, esophageal […]

UT Health San Antonio’s Advanced Interventional Gastroenterology Program is now offering an advanced, minimally invasive procedure that allows physicians to remove large, early-stage colorectal lesions without the need for traditional surgery.

UT Health San Antonio’s Mays Cancer Center has been named among the nation’s leading hospitals and health systems for excellence in oncology programs, according to Becker’s Hospital Review.